Receive our newsletter – data, insights and analysis delivered to you
  1. News
December 6, 2016

Noveome begins Phase II trial of ST266 to treat allergic conjunctivitis

US-based clinical stage biotherapeutics company Noveome has begun its Phase II clinical trial of ST266 to treat allergic conjunctivitis.

US-based clinical stage biotherapeutics company Noveome has begun its Phase II clinical trial of ST266 to treat allergic conjunctivitis.

ST266 is a secretome, otherwise known as a rich, complex solution of molecules released from proprietary cells. The ST266 secretome contains many biologically active molecules present in physiological concentrations.

As a mixture of biomolecules, this secretome is important during biologic processes that are available at sufficiently low levels to avoid negative effects.

The Phase II multi-centre, double-blind, randomised, placebo-controlled study is being conducted to test the efficacy, safety and tolerability of ST266 ophthalmic drops to treat the signs and symptoms of allergic conjunctivitis.

The trial will be conducted based on Ora’s Conjunctival Allergen Challenge (Ora-CAC) Model, approved by the US Food and Drug Administration (FDA) as the standard methodology for evaluation of the efficacy of products for allergic conjunctivitis.

"There is a need to develop new treatment options that are better tolerated and more effective than conventional allergy therapies."

Allergic conjunctivitis is a commonly occurring allergic condition caused by exposure to an allergen such as dust, pollen and mould, which cause mast cell degranulation and the release of histamine.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

It leads to symptoms such as ocular itching and redness, chemosis and blepharitis.

A late phase reaction triggered by the ailment occurs when mast cells synthesise and release a variety of pro-inflammatory mediators, which increase vascular permeability and necessitate treatment with steroids.

The study is primarily focused on measuring ocular itching and conjunctival redness over time, following an allergen challenge.

Noveome chief medical officer Kenneth Mandell said: “There is a need to develop new treatment options that are better tolerated and more effective than conventional allergy therapies.

“By restoring paracrine signalling between cells to help reduce inflammation, ST266 holds promise as a new approach to treating allergic conjunctivitis and other forms of ocular inflammation.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU